Arcturus Therapeutics, Inc.
15
2
2
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
20.0%
3 terminated/withdrawn out of 15 trials
75.0%
-11.5% vs industry average
7%
1 trials in Phase 3/4
56%
5 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients
Role: collaborator
Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults
Role: lead
Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults
Role: lead
The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)
Role: collaborator
A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults
Role: lead
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
Role: lead
Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults
Role: lead
Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810
Role: lead
A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults
Role: lead
A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD
Role: lead
Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021
Role: lead
Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.
Role: lead
Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency
Role: lead
Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects
Role: lead
Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects
Role: lead
All 15 trials loaded